<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4071">
  <stage>Registered</stage>
  <submitdate>17/04/2013</submitdate>
  <approvaldate>17/04/2013</approvaldate>
  <nctid>NCT01835535</nctid>
  <trial_identification>
    <studytitle>Continued Safety and Performance of the TIVUS System</studytitle>
    <scientifictitle>Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) System for Renal Denervation in Patients With Resistant Hypertension</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CLN02-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension, Resistant to Conventional Therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - TIVUS

Experimental: Severe Resistant HTN - Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater


Treatment: devices: TIVUS


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in office Systolic Blood Pressure (SBP) from baseline to 6-month</outcome>
      <timepoint>6 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural complications</outcome>
      <timepoint>30 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Events (MAE)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preservation of renal function</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular complications</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure reduction</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient is = 18 and = 80 years of age

          -  For Cohort A: Documented office systolic blood pressure &gt; 160 mmHg (&gt; 150 mmHg for
             diabetic patients); For Cohort B: Documented office systolic blood pressure &gt; 140 mmHg
             (&gt; 130 mmHg for diabetic patients); For Cohort C: Documented office systolic blood
             pressure &gt; 150 mmHg (&gt; 140 mmHg for diabetic patients)

          -  Documented 24 hour systolic ABPM &gt; 135 mmHg

          -  Adherence to a stable drug regimen

          -  For patients in Cohort C only: Documented renal denervation procedure with any RF
             technology 12 months or more prior to screening

          -  Suitable renal artery anatomy

          -  Male or non-pregnant / non-lactating female

          -  Patient understands the nature of the procedure and provides written informed consent

          -  Patient is willing and able to comply with the specified study requirements and
             follow-up evaluations</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  eGFR &lt; 45mL/min/1.73m2

          -  Documented primary pulmonary hypertension

          -  Patient experienced &gt;1 episode of orthostatic hypotension coupled with syncope

          -  Documented indicator of a secondary renal hypertension

          -  History of myocardial infarction, unstable angina pectoris, or a cerebrovascular
             accident within 6 months

          -  Planned major surgery or cardiovascular intervention in the next 6 months

          -  Surgery or cardiovascular intervention in the previous 3 months

          -  Hemodynamically significant valvular heart disease

          -  Severe debilitating lung disease

          -  Patient on anticoagulant therapy that cannot be temporarily withheld for performing
             catheterization

          -  Patient has a single functioning kidney

          -  Documented thrombocytopenia, clotting disorders or aortic aneurysms

          -  Moribund patient, or patient with comorbidities limiting life expectancy to less than
             one year

          -  Contraindication to recommended study medications or intravascular contrast material
             that cannot be adequately controlled with pre-medication

          -  Concurrent enrollment in another trial

          -  Main renal arteries &lt; 4 mm in lumen diameter or &lt; 20 mm in length

          -  Aorto-renal angle that prevents a safe cannulation of the renal artery

          -  Severe common femoral artery, common and/or external iliac artery, renal, iliac or
             aortic calcification or tortuosity that may compromise the safe performance and
             completion of the procedure

          -  Hemodynamically or anatomically significant renal artery abnormality or stenosis in
             either renal artery

          -  Any renal artery stenosis &gt; 50% by visual assessment

          -  Any renal artery aneurysm in either renal artery

          -  A history of prior renal artery balloon angioplasty or stenting (for patients in
             Cohort A and B only, also a history of prior renal denervation at any time)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cardiosonic</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The TIVUS II is a prospective, multicenter, non-randomized, open-label clinical study of the
      safety and performance of the TIVUS System consisting of three (3) concurrent cohorts:

        -  TIVUS Severe Resistant HTN Cohort

        -  TIVUS Moderate Resistant HTN Cohort

        -  TIVUS Failed RF Therapy Cohort</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01835535</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Jonas, MD</name>
      <address>Kaplan Medical Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>